Genmab’s Epcoritamab (DuoBody-CD3xCD20) Receives the US FDA’s Orphan-Drug Designation for the Treatment of Follicular Lymphoma
Shots:
- The US FDA has granted ODD to epcoritamab for the treatment of FL. The therapy is being co-developed by Genmab and AbbVie
- Epcoritamab is currently being studied as a treatment option for the treatment of FL in multiple clinical trials including the P-I/II (EPCORE NHL-1) study for r/r B-NHL while the P-Ib/II trial for DLBCL or FL & r/r B-NHL
- Epcoritamab is an IgG1-bispecific Ab that has been developed using Genmab’s DuoBody technology & is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. The therapy has the potential to bind to CD3 on T cells & CD20 on B cells & induces T cell-mediated killing of lymphoma B cells
Ref: Globe Newswire | Image: Genmab
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
